Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

Topical Bimatoprost in the Treatment of Migraine

Phase 2

Conditions: Migraine Disorders
Headache Disorders

Interventions: Drug: Control
Drug: Bimatoprost Topical Solution

First Posted Date: 2018-02-05

Last Posted Date: 2019-04-26

Lead Sponsor: Manistee Partners

Target Recruit Count: 70

Registration Number: NCT03419715

Locations: 🇺🇸
Omega Medical Research, Warwick, Rhode Island, United States
🇺🇸
CTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States

Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Normal Tension Glaucoma

Interventions: Drug: brimonidine tartrate/timolol malate Ophthalmic Solution
Drug: bimatoprost ophthalmic solution 0.01%

First Posted Date: 2016-08-11

Last Posted Date: 2018-08-31

Lead Sponsor: Allergan

Target Recruit Count: 118

Registration Number: NCT02863705

Locations: 🇰🇷
Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷
Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of
🇰🇷
Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of

and more 6 locations

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Phase 1

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Bimatoprost 1% Formulation A
Drug: Bimatoprost 1% Formulation B

First Posted Date: 2016-07-28

Last Posted Date: 2016-10-26

Lead Sponsor: Allergan

Target Recruit Count: 11

Registration Number: NCT02848300

Locations: 🇺🇸
DermResearch, LLC, Austin, Texas, United States

Topical Bimatoprost for Chemical Blepharoplasty

Early Phase 1

Completed

Conditions: Dermatochalasis

Interventions: Drug: bimatoprost 0.03% ophthalmic solution

First Posted Date: 2016-07-13

Last Posted Date: 2021-03-05

Lead Sponsor: Tulane University

Target Recruit Count: 15

Registration Number: NCT02830776

Locations: 🇺🇸
Tulane Department of Dermatology, New Orleans, Louisiana, United States

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Fixed Combination
Drug: Timolol
Drug: Bimatoprost
Device: Placebo Segment
Drug: Timolol 0.5%

First Posted Date: 2016-04-19

Last Posted Date: 2019-02-25

Lead Sponsor: ForSight Vision5, Inc.

Target Recruit Count: 55

Registration Number: NCT02742649

Locations: 🇵🇦
Clinica de Ojos Orillac - Calvo, Panama City, Panama

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Phase 1

Terminated

Conditions: Alopecia, Androgenetic
Alopecia
Baldness

Interventions: Drug: Bimatoprost

First Posted Date: 2016-02-08

Last Posted Date: 2017-03-17

Lead Sponsor: Allergan

Target Recruit Count: 53

Registration Number: NCT02676310

Locations: 🇺🇸
J&S Studies Inc., College Station, Texas, United States
🇺🇸
E&R Research Foundation, Lynchburg, Virginia, United States
🇺🇸
DermResearch, LLC, Austin, Texas, United States

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Open-Angle Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: Sham Bimatoprost SR
Procedure: Selective Laser Trabeculoplasty
Procedure: Sham Selective Laser Trabeculoplasty

First Posted Date: 2015-12-22

Last Posted Date: 2022-02-23

Lead Sponsor: Allergan

Target Recruit Count: 144

Registration Number: NCT02636946

Locations: 🇺🇸
Wolstan & Goldberg Eye Associates, Torrance, California, United States
🇺🇸
Asheville Eye Associates, Asheville, North Carolina, United States
🇩🇰
Glostrup Hospital, Glostrup, Hovedstaden, Denmark

and more 30 locations

Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.03% plus timolol 0.5%

First Posted Date: 2015-10-08

Last Posted Date: 2018-07-05

Lead Sponsor: Allergan

Target Recruit Count: 750

Registration Number: NCT02571712

Locations: 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳
Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China

and more 12 locations

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Phase 2

Completed

Conditions: Primary Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost

First Posted Date: 2015-09-01

Last Posted Date: 2019-04-02

Lead Sponsor: ForSight Vision5, Inc.

Target Recruit Count: 81

Registration Number: NCT02537015

Locations: 🇺🇸
Sall Medical Research Center, Artesia, California, United States
🇺🇸
Total Eye Care, Memphis, Tennessee, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States

and more 6 locations

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: Bimatoprost SR
Drug: Sham Bimatoprost SR
Procedure: Selective Laser Trabeculoplasty
Procedure: Sham Selective Laser Trabeculoplasty

First Posted Date: 2015-07-24

Last Posted Date: 2024-05-10

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT02507687

Locations: 🇺🇸
Wolstan & Goldberg Eye Associates /ID# 235166, Torrance, California, United States
🇺🇸
Trinity Research Group /ID# 234598, Dothan, Alabama, United States
🇺🇸
Houston Eye Associates /ID# 237883, Houston, Texas, United States

and more 92 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy